Abstract
In 2001 an outbreak of Neisseria menigitidis serogroup C occurred in the province of Antwerp (Belgium). Over a year the incidence rate of meningococcal disease (MD) increased from 3.9 per 100,000 to 9.1 per 100,000 with a shift from serogroup B (87%) in 2000 to serogroup C (66%) in 2001. The most prominent phenotype was C:2a:P1.2,5. The incidence rate for serogroup C MD increased from 0.4 per 100,000 to 4.5 per 100,000 in 2001. The case fatality rate was 6.7% in 2001. After the introduction of a mass vaccination campaign with a conjugated vaccine against serogroup C MD the incidence of serogroup C MD fell from 4.5 to 1.8 per 100,000. As a result of the analysis of this outbreak, it was proposed to offer a vaccine against serogroup C to all people under 19 years of age. Part of this plan has been implemented to date in Belgium.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Swartz B, Moore PS, Broome CV. The global epidemiology of meningococcal diseases. Clin Micrbiol Rev 1989; 2: S118–S124.
Van Looveren M, Carion F, Van Damme P, Goossens H. Surveillance of meningococcal infections in Belgium. Clin Microbiol Infect 1998; 4: 224–228.
Van Looveren M, Caugant DA, Chapelle S, Carion F, Goossens H. Interpreting the rising incidence of meningococcal disease in Belgium: The contribution of molecular typing. J Med Microbiol 2001; 50: 986–990.
Carion F, Van Looveren M, Goossens H. New epidemiolgical features of meningococcal disease in Belgium. Eurosurveill Monthly 1997; 10: 80.
Carion F. Annual report of N. meningitidis reference laboratory, Belgium 2001. Institute of Public Health, Brussels, 2002; pp. 1–10.
Maes I, De Schrijver K. Het komen en gaan van een meningokokkenepidemie. Epidemiologisch Bulletin van de Vlaamse Gemeenschap 2002; 2: 20–24.
Top G. Registratie van infectieziekten Vlaamse gezondheidsinspectie 2000-2002. Brussel, 2002.
Samuelsson S. Meningococcal disease - still a major challenge. Commun Dis Public Health 2002; 5(3): 78–81.
Davison KL, Ramsay ME, Crowcroft NS, et al. Estimating the burden of serogroup C meningococcal disease in England and Wales. Commun Dis Public Health 2002; 5(2): 213–219.
Hubert B, Caugant DA. Recent changes in meningococcal disease in Europe. Eurosurveill Monthly 1997; 10: 69–71.
Tyrell GJ, Chui L, Johnson M, et al. Outbreak of Neisseria meningitidis, Edmonton, Alberta, Canada. Emerg Infect Dis 2002; 8, url www.cdc.gov/ncidod/ EID/vol8no7/02-0157htm.
CDSC. Vaccination programme for C meningoccal infection is launched. Commun Dis Rep CDR Wkl 1999; 9: 261–264.
Maiden MCJ, Stuart JM for the UK Meningococcal Carriage Group. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet 2002; 359: 1829–1830.
Alcalá B, Arreaza L, Salcedo C, Uria MJ, De la Fuente L, Vázquez. Capsule Switching among C:2b:P1.2,5 Meningococcal Epidemic Strains after Mass Immunization Campaign, Spain. Emerg Infect Dis 2002; 8: 1512–1514.
Krause G, Blackmore C, Wirsma S, Lesneski C, Gauch L, Hopkins RS. Mass Vaccination campaign Following Community outbreak of Meningococcal Disease. Emerg Infect Dis 2002; 8: 1398–1403.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
De Schrijver, K., Maes, I. An outbreak of serogroup C meningococcal disease in the province of Antwerp (Belgium) in 2001–2002. Eur J Epidemiol 18, 1073–1077 (2003). https://doi.org/10.1023/A:1026100321871
Issue Date:
DOI: https://doi.org/10.1023/A:1026100321871